Key result
Silencing RGS4 in endothelial cells increased constitutive basolateral secretion of von Willebrand factor and enhanced platelet recruitment onto the subendothelial matrix under flow.
Why the study?
To determine whether the constitutive release of subendothelial von Willebrand factor is regulated and the potential functional consequences.
Does silencing RGS4 increase constitutive basolateral secretion of VWF and platelet recruitment in HUVECs?
Does silencing RGS4 increase constitutive basolateral secretion of VWF and platelet recruitment in HUVECs?
RGS4 regulates the constitutive secretion of subendothelial VWF, introducing a novel control mechanism over VWF function and platelet recruitment.
RGS4 may regulate endothelial VWF secretion; leaves open its role in thrombosis models and clinical relevance.
The haemostatic protein von Willebrand factor (VWF) exists in plasma and subendothelial pools. The plasma pools are secreted from endothelial storage granules, Weibel-Palade bodies (WPBs), by basal secretion with a contribution from agonist-stimulated secretion, and the subendothelial pool is secreted into the subendothelial matrix by a constitutive pathway not involving WPBs. We set out to determine whether the constitutive release of subendothelial VWF is actually regulated and, if so, what functional consequences this might have. Constitutive VWF secretion can be increased by a range of factors, including changes in VWF expression, levels of TNF and other environmental cues. An RNA-seq analysis revealed that expression of regulator of G protein signalling 4 (RGS4) was reduced in endothelial cells (HUVECs) grown under these conditions. siRNA RGS4 treatment of HUVECs increased constitutive basolateral secretion of VWF, probably by affecting the anterograde secretory pathway. In a simple model of endothelial damage, we show that RGS4-silenced cells increased platelet recruitment onto the subendothelial matrix under flow. These results show that changes in RGS4 expression alter levels of subendothelial VWF, affecting platelet recruitment. This introduces a novel control over VWF function.
No takes yet. Share an insight, caveat, or question.
Patella et al. (2020) studied this question. siRNA RGS4 treatment was evaluated on Constitutive basolateral secretion of VWF and platelet recruitment. Silencing RGS4 in endothelial cells increased constitutive basolateral secretion of von Willebrand factor and enhanced platelet recruitment onto the subendothelial matrix under flow.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: